On March 1, 2024, the U.S. FDA approved RYBREVANT in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR ...
Some results have been hidden because they may be inaccessible to you